🚀 VC round data is live in beta, check it out!
Yifan Pharmaceutical Valuation Multiples
Discover revenue and EBITDA valuation multiples for Yifan Pharmaceutical and similar public comparables like PegBio, Hepalink, Stoke Therapeutics, Natco Pharma and more.
Yifan Pharmaceutical Overview
About Yifan Pharmaceutical
Yifan Pharmaceutical Co Ltd is a China-based company engaged in R&D and production company focusing on the pharmaceutical and health sectors. Its vision is to develop drugs with definite clinical values, to help disease-afflicted patients regain health. The group focuses on four business areas such as biologics, small molecules, synthetic biologics, and special traditional Chinese medicines (TCMs). The products of the company are Ryzneuta, Plerixafor Injection, Vincristine Sulfate, Skin Allergy Reli, and Others.
Founded
1994
HQ
Employees
1.5K
Website
Financials (LTM)
EV
$2B
Yifan Pharmaceutical Financials
Yifan Pharmaceutical reported last 12-month revenue of $939M and EBITDA of $181M.
In the same LTM period, Yifan Pharmaceutical generated $471M in gross profit, $181M in EBITDA, and $98M in net income.
Revenue (LTM)
Yifan Pharmaceutical P&L
In the most recent fiscal year, Yifan Pharmaceutical reported revenue of $756M and EBITDA of $132M.
Yifan Pharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $939M | XXX | $756M | XXX | XXX | XXX |
| Gross Profit | $471M | XXX | $359M | XXX | XXX | XXX |
| Gross Margin | 50% | XXX | 47% | XXX | XXX | XXX |
| EBITDA | $181M | XXX | $132M | XXX | XXX | XXX |
| EBITDA Margin | 19% | XXX | 17% | XXX | XXX | XXX |
| EBIT Margin | 10% | XXX | 12% | XXX | XXX | XXX |
| Net Profit | $98M | XXX | $57M | XXX | XXX | XXX |
| Net Margin | 10% | XXX | 7% | XXX | XXX | XXX |
| Net Debt | — | — | $117M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Yifan Pharmaceutical Stock Performance
Yifan Pharmaceutical has current market cap of $2B, and enterprise value of $2B.
Market Cap Evolution
Yifan Pharmaceutical's stock price is $1.80.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $2B | 0.0% | XXX | XXX | XXX | $0.05 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialYifan Pharmaceutical Valuation Multiples
Yifan Pharmaceutical trades at 2.6x EV/Revenue multiple, and 13.4x EV/EBITDA.
EV / Revenue (LTM)
Yifan Pharmaceutical Financial Valuation Multiples
As of April 20, 2026, Yifan Pharmaceutical has market cap of $2B and EV of $2B.
Equity research analysts estimate Yifan Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Yifan Pharmaceutical has a P/E ratio of 22.3x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/Revenue | 2.6x | XXX | 3.2x | XXX | XXX | XXX |
| EV/EBITDA | 13.4x | XXX | 18.3x | XXX | XXX | XXX |
| EV/EBIT | 26.2x | XXX | 27.4x | XXX | XXX | XXX |
| EV/Gross Profit | 5.2x | XXX | 6.8x | XXX | XXX | XXX |
| P/E | 22.3x | XXX | 38.6x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 1315.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Yifan Pharmaceutical Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Yifan Pharmaceutical Margins & Growth Rates
Yifan Pharmaceutical's revenue in the last 12 month grew by 17%.
Yifan Pharmaceutical's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.2M for the same period.
Yifan Pharmaceutical's rule of 40 is 37% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Yifan Pharmaceutical's rule of X is 62% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Yifan Pharmaceutical Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 17% | XXX | 18% | XXX | XXX | XXX |
| EBITDA Margin | 19% | XXX | 17% | XXX | XXX | XXX |
| EBITDA Growth | 18% | XXX | 28% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 37% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 62% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 24% | XXX | 22% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 8% | XXX | 7% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 5% | XXX | 6% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 36% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Yifan Pharmaceutical Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Yifan Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| PegBio | XXX | XXX | XXX | XXX | XXX | XXX |
| Hepalink | XXX | XXX | XXX | XXX | XXX | XXX |
| Stoke Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Natco Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Eris Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Yifan Pharmaceutical M&A Activity
Yifan Pharmaceutical acquired XXX companies to date.
Last acquisition by Yifan Pharmaceutical was on XXXXXXXX, XXXXX. Yifan Pharmaceutical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Yifan Pharmaceutical
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialYifan Pharmaceutical Investment Activity
Yifan Pharmaceutical invested in XXX companies to date.
Yifan Pharmaceutical made its latest investment on XXXXXXXX, XXXXX. Yifan Pharmaceutical invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Yifan Pharmaceutical
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Yifan Pharmaceutical
| When was Yifan Pharmaceutical founded? | Yifan Pharmaceutical was founded in 1994. |
| Where is Yifan Pharmaceutical headquartered? | Yifan Pharmaceutical is headquartered in China. |
| How many employees does Yifan Pharmaceutical have? | As of today, Yifan Pharmaceutical has over 1K employees. |
| Is Yifan Pharmaceutical publicly listed? | Yes, Yifan Pharmaceutical is a public company listed on Shenzhen Stock Exchange. |
| What is the stock symbol of Yifan Pharmaceutical? | Yifan Pharmaceutical trades under 002019 ticker. |
| When did Yifan Pharmaceutical go public? | Yifan Pharmaceutical went public in 2004. |
| Who are competitors of Yifan Pharmaceutical? | Yifan Pharmaceutical main competitors are PegBio, Hepalink, Stoke Therapeutics, Natco Pharma. |
| What is the current market cap of Yifan Pharmaceutical? | Yifan Pharmaceutical's current market cap is $2B. |
| What is the current revenue of Yifan Pharmaceutical? | Yifan Pharmaceutical's last 12 months revenue is $939M. |
| What is the current revenue growth of Yifan Pharmaceutical? | Yifan Pharmaceutical revenue growth (NTM/LTM) is 17%. |
| What is the current EV/Revenue multiple of Yifan Pharmaceutical? | Current revenue multiple of Yifan Pharmaceutical is 2.6x. |
| Is Yifan Pharmaceutical profitable? | Yes, Yifan Pharmaceutical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Yifan Pharmaceutical? | Yifan Pharmaceutical's last 12 months EBITDA is $181M. |
| What is Yifan Pharmaceutical's EBITDA margin? | Yifan Pharmaceutical's last 12 months EBITDA margin is 19%. |
| What is the current EV/EBITDA multiple of Yifan Pharmaceutical? | Current EBITDA multiple of Yifan Pharmaceutical is 13.4x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.